OncoMatch

OncoMatch/Breast Cancer/PGR (PR)

Breast CancerPGR (PR) Clinical Trials

133 recruiting trials·Updated daily from ClinicalTrials.gov

Progesterone receptor (PR) expression is assessed alongside ER as part of hormone receptor testing and influences prognosis and treatment planning. PR positivity typically co-occurs with ER positivity and correlates with better endocrine therapy response. Trials enrolling HR+ patients (ER+ and/or PR+) include CDK4/6 inhibitor combinations, PI3K/AKT pathway agents, antibody-drug conjugates, and endocrine backbone strategies.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting PGR (PR) Breast Cancer trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 31535 US sites

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NRG Oncology

Phase 3819 US sites

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NRG Oncology

Phase 3184 US sites

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Gilead Sciences

Phase 363 US sites

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Novartis Pharmaceuticals

Phase 3

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Hoffmann-La Roche

Phase 3

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Peking University

Additional trials

More PGR (PR) Breast Cancer trials

See all in search →
Phase 2
23 international trials (no US sites)
NCT06606730Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast CancerPhase 3NCT06781996A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast CancerPhase 3NCT06926868A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Phase 2/Phase 3NCT06072612Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 3NCT06081959Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerPhase 3NCT06977893Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)Phase 3NCT05904964Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)Phase 3NCT05212454Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High RisksPhase 3NCT06839001CRYoablation for Small Tumors As Local Treatment - SIX TrialPhase 3NCT07205822A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerPhase 3NCT07019363CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)Phase 3NCT05760612Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabPhase 3NCT03561740A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTientsPhase 3NCT04263298Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerPhase 3NCT06998108Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine TherapyPhase 3NCT05744687Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast CancerPhase 2/Phase 3NCT05063136Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast CancerPhase 3NCT04646759Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerPhase 3NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 3NCT06507618Pre-Operative Window of ET to Inform RT Decisions (POWER II)Phase 3NCT07467330Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentPhase 3NCT07071337A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyPhase 3NCT07174336A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3
Other Breast Cancer biomarkers

Browse other molecular targets with active Breast Cancer trials.

HER2 (ERBB2)ESR1 (ER)PIK3CABRCA1BRCA2
← All Breast Cancer clinical trials